Number of people with at least one episode of HSV-attributable genital ulcer disease was 187.9 and 16.7 million for HSV-2, HSV-1 in 2020<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Dec. 12, 2024 (HealthDay News) — The incidence and prevalence of genital herpes simplex virus (HSV) type 1 and 2 infections are high worldwide, contributing to the burden of genital ulcer disease (GUD), according to a study published online Dec. 10 in Sexually Transmitted Infections<\/em>.<\/p>\n Manale Harfouche, M.P.H., from Weill Cornell Medicine-Qatar in Doha, and colleagues estimated genital infection with both HSV types and associated GUD globally in 2020 using a calibrated mathematical model. A comprehensive systematic review and meta-analyses of HSV prevalence data for all World Health Organization regions were conducted to provide input for the model.<\/p>\n The researchers found 25.6 million people aged 15 to 49 years had new HSV-2 infections and 519.5 million (13.3 percent) had existing (prevalent) HSV-2 infections globally in 2020. In addition, there were 16.8 and 376.2 million people (10.2 percent) aged 15 to 49 years with new genital HSV-1 infections and prevalent genital HSV-1 infections, respectively. The estimated number of people aged 15 to 49 years with at least one episode of HSV-attributable GUD in 2020 was 187.9 and 16.7 million for HSV-2 and HSV-1, respectively, totaling 204.6 million.<\/p>\n “There is a need for HSV prophylactic and therapeutic vaccines as a strategic approach to control transmission and to curb the disease and economic burdens of these infections,” the authors write.<\/p>\n One author disclosed ties to GlaxoSmithKline.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n